Company Overview

Skymab Biotherapeutics is a French biotechnology company pioneering a new generation of Antibody-Drug Conjugates (ADCs) for oncology.
The company has developed a differentiated ADC platform combining proprietary tumor-selective linker technologies, advanced ADC engineering, and expertise in target biology to expand the landscape of actionable ADC targets. At its core is SKYLINK™, a next-generation linker platform designed to maximize anti-tumor efficacy while improving the therapeutic window across multiple ADC modalities.